Johnson & Johnson JNJ MEDTECH — Other (income) expense, net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →
Ask your AI about Johnson & Johnson's medtech — other (income) expense, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Johnson & Johnson's MEDTECH — other (income) expense, net?
- Johnson & Johnson (JNJ) reported MEDTECH — other (income) expense, net of $76M in Q1 2026.
- How has Johnson & Johnson's MEDTECH — other (income) expense, net changed year-over-year?
- Johnson & Johnson's MEDTECH — other (income) expense, net increased by 226.7% year-over-year, from -$60M to $76M.
- What is the long-term trend for Johnson & Johnson's MEDTECH — other (income) expense, net?
- Over 3 years (2022 to 2025), Johnson & Johnson's MEDTECH — other (income) expense, net has grown at a 19.3% compound annual growth rate (CAGR), from $553M to $938M.
- What does MEDTECH — other (income) expense, net mean?
- Includes non-operating income or expenses specific to the MedTech segment, such as gains or losses from asset sales, litigation settlements, or other miscellaneous financial items. It provides a view of the segment's performance outside of core operational activities.